Brimonidine Tartrate + Timolol Maleate
Indications
This eye drops is indicated for the
reduction of elevated intraocular pressure (IOP) in patients with
glaucoma or ocular hypertension.
Pharmacology
This eye drops is comprised of two
components: Brimonidine Tartrate & Timolol Maleate. Brimonidine
Tartrate is a selective alpha-2 adrenergic receptor agonist having a
dual mechanism of action. It decreases aqueous humor production and
increases nonpressure dependent uveoscleral outflow. Timolol Maleate is a
β-adrenergic receptor antagonist that does not have significant
intrinsic sympathomimetic, direct myocardial depressant, or local
anesthetic (membrane-stabilizing) activity. It lowers IOP by reducing
aqueous humor production. Therefore the combination of both drugs gives a
rapid onset of action, with peak ocular hypotensive effect seen within
two hours of administration.
Dosage & Administration
Instill 1 drop in the affected eye(s) twice daily.
Interaction
Specific drug interaction studies have not been conducted.
Contraindications
Contraindicated in patients with
hypersensitivity to any component of this product. Also contraindicated
in bronchial asthma, severe chronic obstructive pulmonary disease, sinus
bradycardia, second or third-degree atrioventricular block, overt
cardiac failure and cardiogenic shock.
Side Effects
The most common side effects are allergic
conjunctivitis, conjunctival folliculosis, conjunctival hyperaemia, eye
pruritus and ocular burning or stinging.
Pregnancy & Lactation
There are no adequate and well-controlled
studies in pregnant women. Combipres should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus.
Timolol has been detected in human milk but it is not known whether
Brimonidine Tartrate is excreted in human milk. A decision should be
made whether to discontinue nursing or to discontinue taking into
account the importance of the drug to the mother.
Precautions & Warnings
Like other topically applied ophthalmic
agents, it may be absorbed systemically. Due to the presence of Timolol,
the same types of cardiovascular and pulmonary adverse reactions as
seen with systemic beta-blockers may occur. Cautions should be exercised
in treating patients with severe or unstable and uncontrolled
cardiovascular or pulmonary diseases.
Use in Special Populations
Use in children: Safety and effectiveness in children below the age of 2 years have not been established.
Use in elderly patients: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
Use in elderly patients: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
Therapeutic Class
Drugs for miotics and glaucoma
Storage Conditions
Store at a cool & dry place, protect
from light. Do not use longer than 30 days after the first opening of
the bottle. Keep out of the reach of children.
Showing 1 to 12 of 12 (1 Pages)